CY1556A - Novel polyesters,their preparation and pharmaceutical use - Google Patents
Novel polyesters,their preparation and pharmaceutical use Download PDFInfo
- Publication number
- CY1556A CY1556A CY1556A CY155691A CY1556A CY 1556 A CY1556 A CY 1556A CY 1556 A CY1556 A CY 1556A CY 155691 A CY155691 A CY 155691A CY 1556 A CY1556 A CY 1556A
- Authority
- CY
- Cyprus
- Prior art keywords
- polyol
- product according
- product
- hydroxyl groups
- acid
- Prior art date
Links
- 229920000728 polyester Polymers 0.000 title claims description 4
- 238000002360 preparation method Methods 0.000 title description 5
- 229920005862 polyol Polymers 0.000 claims description 94
- 150000003077 polyols Chemical class 0.000 claims description 61
- 239000013543 active substance Substances 0.000 claims description 53
- 239000000047 product Substances 0.000 claims description 44
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 30
- 239000011159 matrix material Substances 0.000 claims description 29
- 229920000642 polymer Polymers 0.000 claims description 29
- 239000003094 microcapsule Substances 0.000 claims description 28
- 150000002148 esters Chemical class 0.000 claims description 25
- 239000002253 acid Substances 0.000 claims description 19
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 18
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical group OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 16
- 238000009472 formulation Methods 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 14
- 239000004310 lactic acid Substances 0.000 claims description 13
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims description 12
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims description 11
- 229960002802 bromocriptine Drugs 0.000 claims description 11
- 239000007943 implant Substances 0.000 claims description 11
- 235000014655 lactic acid Nutrition 0.000 claims description 11
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 9
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 9
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 8
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 claims description 7
- 229930195725 Mannitol Natural products 0.000 claims description 7
- 229960004958 ketotifen Drugs 0.000 claims description 7
- 239000000594 mannitol Substances 0.000 claims description 7
- 235000010355 mannitol Nutrition 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 7
- 238000005374 membrane filtration Methods 0.000 claims description 6
- 239000003054 catalyst Substances 0.000 claims description 5
- 125000004122 cyclic group Chemical group 0.000 claims description 5
- 229920000858 Cyclodextrin Polymers 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- JVWLUVNSQYXYBE-UHFFFAOYSA-N Ribitol Natural products OCC(C)C(O)C(O)CO JVWLUVNSQYXYBE-UHFFFAOYSA-N 0.000 claims description 4
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 3
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 claims description 3
- 239000004626 polylactic acid Substances 0.000 claims description 3
- HOSGXJWQVBHGLT-UHFFFAOYSA-N 6-hydroxy-3,4-dihydro-1h-quinolin-2-one Chemical group N1C(=O)CCC2=CC(O)=CC=C21 HOSGXJWQVBHGLT-UHFFFAOYSA-N 0.000 claims description 2
- 239000011149 active material Substances 0.000 claims description 2
- 239000007795 chemical reaction product Substances 0.000 claims description 2
- 230000000063 preceeding effect Effects 0.000 claims 5
- 125000001483 monosaccharide substituent group Chemical group 0.000 claims 1
- 238000007151 ring opening polymerisation reaction Methods 0.000 claims 1
- -1 polyol esters Chemical class 0.000 description 39
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 36
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 32
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 26
- 229960001031 glucose Drugs 0.000 description 19
- 239000008103 glucose Substances 0.000 description 19
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 15
- 229960000448 lactic acid Drugs 0.000 description 13
- 239000002904 solvent Substances 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 230000015556 catabolic process Effects 0.000 description 9
- 238000006731 degradation reaction Methods 0.000 description 9
- 238000005227 gel permeation chromatography Methods 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000001914 filtration Methods 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 229920000747 poly(lactic acid) Polymers 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 125000005474 octanoate group Chemical group 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000003946 Prolactin Human genes 0.000 description 2
- 108010057464 Prolactin Proteins 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 125000001142 dicarboxylic acid group Chemical group 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229940097325 prolactin Drugs 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical group C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- LKDRXBCSQODPBY-ZXXMMSQZSA-N alpha-D-fructopyranose Chemical compound OC[C@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-ZXXMMSQZSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940035678 anti-parkinson drug Drugs 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 229940124433 antimigraine drug Drugs 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- NOJMTMIRQRDZMT-GSPXQYRGSA-N bromocriptine methanesulfonate Chemical compound CS(O)(=O)=O.C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 NOJMTMIRQRDZMT-GSPXQYRGSA-N 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000012667 polymer degradation Methods 0.000 description 1
- 239000005076 polymer ester Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/66—Polyesters containing oxygen in the form of ether groups
- C08G63/664—Polyesters containing oxygen in the form of ether groups derived from hydroxy carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
- C08G63/06—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids
- C08G63/08—Lactones or lactides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Polyesters Or Polycarbonates (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH4671/83A CH656884A5 (de) | 1983-08-26 | 1983-08-26 | Polyolester, deren herstellung und verwendung. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1556A true CY1556A (en) | 1991-03-22 |
Family
ID=4280440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY1556A CY1556A (en) | 1983-08-26 | 1991-03-22 | Novel polyesters,their preparation and pharmaceutical use |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US5922682A (ja) |
| JP (1) | JPH0819226B2 (ja) |
| AT (1) | AT395584B (ja) |
| AU (1) | AU575066B2 (ja) |
| BE (1) | BE900406A (ja) |
| CH (1) | CH656884A5 (ja) |
| CY (1) | CY1556A (ja) |
| DE (1) | DE3430852C2 (ja) |
| DK (1) | DK173556B1 (ja) |
| ES (1) | ES8706750A1 (ja) |
| FR (1) | FR2551072B1 (ja) |
| GB (1) | GB2145422B (ja) |
| GR (1) | GR80184B (ja) |
| HK (1) | HK67390A (ja) |
| HU (1) | HU195426B (ja) |
| IE (1) | IE58818B1 (ja) |
| IL (1) | IL72763A (ja) |
| IT (1) | IT1176629B (ja) |
| LU (1) | LU85514A1 (ja) |
| MY (1) | MY101861A (ja) |
| NL (2) | NL190415C (ja) |
| NZ (1) | NZ209335A (ja) |
| PH (1) | PH23556A (ja) |
| PT (1) | PT79129B (ja) |
| SE (1) | SE462098B (ja) |
| SG (1) | SG53590G (ja) |
| ZA (1) | ZA846634B (ja) |
Families Citing this family (107)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2551756B2 (ja) * | 1985-05-07 | 1996-11-06 | 武田薬品工業株式会社 | ポリオキシカルボン酸エステルおよびその製造法 |
| DE3641692A1 (de) * | 1986-12-06 | 1988-06-09 | Boehringer Ingelheim Kg | Katalysatorfreie resorbierbare homopolymere und copolymere |
| GB8801863D0 (en) * | 1988-01-28 | 1988-02-24 | Fulmer Yarsley Ltd | Pharmaceutical formulations with controlled drug release |
| US5247013A (en) * | 1989-01-27 | 1993-09-21 | Mitsui Toatsu Chemicals, Inc. | Biocompatible polyester and production thereof |
| WO1990008793A1 (en) * | 1989-01-27 | 1990-08-09 | Mitsui Toatsu Chemicals, Inc. | Biocompatible polyester and production thereof |
| PH30995A (en) * | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| HU221294B1 (en) * | 1989-07-07 | 2002-09-28 | Novartis Ag | Process for producing retarde compositions containing the active ingredient in a polymeric carrier |
| US5538739A (en) * | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
| US6353030B1 (en) * | 1990-08-01 | 2002-03-05 | Novartis Ag | Relating to organic compounds |
| MY108621A (en) * | 1990-08-01 | 1996-10-31 | Novartis Ag | Polylactide preparation and purification |
| KR920702376A (ko) * | 1990-10-01 | 1992-09-03 | 후지다 히로미찌 | 시클로덱스트린 폴리머 및 그 폴리머를 이용한 시클로덱스트린막 |
| US5225521A (en) * | 1991-12-31 | 1993-07-06 | E. I. Du Pont De Nemours And Company | Star-shaped hydroxyacid polymers |
| US6326458B1 (en) | 1992-01-24 | 2001-12-04 | Cargill, Inc. | Continuous process for the manufacture of lactide and lactide polymers |
| US5258488A (en) * | 1992-01-24 | 1993-11-02 | Cargill, Incorporated | Continuous process for manufacture of lactide polymers with controlled optical purity |
| US5247059A (en) * | 1992-01-24 | 1993-09-21 | Cargill, Incorporated | Continuous process for the manufacture of a purified lactide from esters of lactic acid |
| US5142023A (en) * | 1992-01-24 | 1992-08-25 | Cargill, Incorporated | Continuous process for manufacture of lactide polymers with controlled optical purity |
| US5247058A (en) * | 1992-01-24 | 1993-09-21 | Cargill, Incorporated | Continuous process for manufacture of lactide polymers with controlled optical purity |
| US6005067A (en) * | 1992-01-24 | 1999-12-21 | Cargill Incorporated | Continuous process for manufacture of lactide polymers with controlled optical purity |
| GB9206736D0 (en) * | 1992-03-27 | 1992-05-13 | Sandoz Ltd | Improvements of organic compounds and their use in pharmaceutical compositions |
| FR2692167B1 (fr) * | 1992-06-16 | 1994-09-16 | Centre Nat Rech Scient | Préparation et application de nouveaux systèmes colloïdaux nanovésiculaires dispersibles à base de cyclodextrine, sous forme de nanocapsules. |
| FR2692168B1 (fr) * | 1992-06-16 | 1995-03-24 | Centre Nat Rech Scient | Préparation et utilisation de nouveaux systèmes colloïdaux dispersibles à base de cyclodextrine, sous forme de nanosphères. |
| AU4198793A (en) † | 1992-07-24 | 1994-01-27 | Takeda Chemical Industries Ltd. | Microparticle preparation and production thereof |
| US5338822A (en) * | 1992-10-02 | 1994-08-16 | Cargill, Incorporated | Melt-stable lactide polymer composition and process for manufacture thereof |
| US6005068A (en) | 1992-10-02 | 1999-12-21 | Cargill Incorporated | Melt-stable amorphous lactide polymer film and process for manufacture thereof |
| DE69322155T2 (de) * | 1992-10-02 | 1999-08-19 | Cargill | Papier mit einer beschichtung aus schmelzstabilem polymer und dessen verfahren zur herstellung |
| ES2156876T3 (es) * | 1992-10-02 | 2001-08-01 | Cargill Inc | Tejido en polimero lactido, estable en estado fundido, y su proceso para fabricarlo. |
| TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
| US5594091A (en) * | 1994-02-21 | 1997-01-14 | Takeda Chemical Industries, Ltd. | Matrix for sustained-release preparation |
| DE4406172C2 (de) * | 1994-02-25 | 2003-10-02 | Sanol Arznei Schwarz Gmbh | Polyester |
| ES2078190B1 (es) * | 1994-05-20 | 1996-08-01 | Cusi Lab | Procedimiento para el recubrimiento de goticulas o particulas de tamaño nanometrico. |
| US5817728A (en) * | 1995-03-16 | 1998-10-06 | Mitsui Chemicals, Inc. | Preparation of degradable copolymers |
| US5914381A (en) * | 1996-09-12 | 1999-06-22 | Mitsui Chemicals, Inc. | Degradable polymer and preparation process of the same |
| US5916883A (en) * | 1996-11-01 | 1999-06-29 | Poly-Med, Inc. | Acylated cyclodextrin derivatives |
| AR020650A1 (es) * | 1998-08-10 | 2002-05-22 | Poly Med Inc | Polimeros fosforilados y conjugados de los mismos |
| DE19839515B4 (de) * | 1998-08-29 | 2012-02-02 | Nanohale Gmbh | Neue pharmazeutische Zubereitung, enthaltend kolloidale Polymer-Wirkstoff-Assoziate, insbesondere auch für mucosale Wirkstoffverabreichung |
| WO2000025826A1 (en) | 1998-11-02 | 2000-05-11 | Societe De Conseils De Recherches Et D'applications Scientifiques Sas | Lactone bearing absorbable polymers |
| US6451346B1 (en) * | 1998-12-23 | 2002-09-17 | Amgen Inc | Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents |
| US8614291B2 (en) | 1999-08-10 | 2013-12-24 | Poly-Med, Inc. | Phosphorylated polymers and conjugates thereof |
| US6461631B1 (en) | 1999-11-16 | 2002-10-08 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| US6616944B2 (en) * | 2000-03-08 | 2003-09-09 | Medinnova Gesellschaft Fur Medizinsche Innovationen Aus Adkademischer Forschung Mbh | Self-assembling colloidal carriers for protein delivery |
| ATE466042T1 (de) * | 2000-03-08 | 2010-05-15 | Lab Internat Barbados Srl | Kolloidale nanopartikuläre träger enthaltend geladene oder ungeladene wasserlösliche kammpolymere und deren verwendung zur mucosalen applikation |
| WO2002012369A1 (en) * | 2000-08-07 | 2002-02-14 | Wako Pure Chemical Industries, Ltd. | Lactic acid polymer and process for producing the same |
| DE10055742B4 (de) * | 2000-11-10 | 2006-05-11 | Schwarz Pharma Ag | Neue Polyester, Verfahren zu ihrer Herstellung und aus den Polyestern hergestellte Depot-Arzneiformen |
| DE10111767B4 (de) * | 2001-03-12 | 2005-03-24 | Schwarz Pharma Ag | Verfahren zur Herstellung von Polyestern aus Hydroxycarbonsäuren und Polyolen durch Polykondensation |
| TW200526267A (en) | 2001-06-29 | 2005-08-16 | Takeda Chemical Industries Ltd | Controlled release composition and method of producing the same |
| GB0122318D0 (en) * | 2001-09-14 | 2001-11-07 | Novartis Ag | Organic compounds |
| BRPI0213564B8 (pt) | 2001-10-30 | 2021-05-25 | Novartis Ag | formulação depósito e micropartícula compreendendo iloperidona e polímero poli(d,l-lactídeo-co-glicolídeo), e processo para preparação da referida micropartícula |
| EP2316469A1 (en) | 2002-02-22 | 2011-05-04 | Shire LLC | Delivery system and methods for protecting and administering dextroamphetamine |
| GB0216416D0 (en) | 2002-07-15 | 2002-08-21 | Novartis Ag | Organic compounds |
| US20040097419A1 (en) * | 2002-11-19 | 2004-05-20 | Holger Petersen | Organic compounds |
| ATE463244T1 (de) * | 2004-10-25 | 2010-04-15 | Bausch & Lomb | Ophthalmische zusammensetzungen und verfahren zu deren verwendung |
| US20060089384A1 (en) * | 2004-10-25 | 2006-04-27 | Minno George E | Ophthalmic compositions and methods of using the same |
| GB2422839B (en) | 2005-01-11 | 2009-06-24 | Schlumberger Holdings | Degradable polymers for wellbore fluids and processes |
| US7794495B2 (en) * | 2006-07-17 | 2010-09-14 | Advanced Cardiovascular Systems, Inc. | Controlled degradation of stents |
| CN101583651A (zh) * | 2006-09-04 | 2009-11-18 | 生物能源株式会社 | 聚酯多元醇 |
| CN100460441C (zh) * | 2006-09-25 | 2009-02-11 | 南开大学 | 生物可降解星型结构聚乙丙交酯载药微球及其制备方法 |
| AR064381A1 (es) | 2006-12-18 | 2009-04-01 | Takeda Pharmaceutical | Composicion de liberacion sostenida y metodos para producirla |
| PE20090387A1 (es) | 2007-05-24 | 2009-04-28 | Novartis Ag | Formulacion de pasireotida |
| KR101542433B1 (ko) | 2008-02-22 | 2015-08-06 | 도레이 카부시키가이샤 | 마이크로 입자 및 그 의약품 조성물 |
| EP2213307A1 (en) | 2009-02-03 | 2010-08-04 | Novartis AG | Injectable depot formulations |
| EP2172189A1 (en) | 2008-10-01 | 2010-04-07 | Novartis AG | Pharmaceutical Compositions |
| US20100086597A1 (en) * | 2008-10-06 | 2010-04-08 | Oakwood Laboratories LLC | Microspheres for the sustained release of octreotide with a low initial burst |
| US20100086596A1 (en) * | 2008-10-06 | 2010-04-08 | Oakwood Laboratories LLC | Microspheres for releasing an octreotide compound without an initial time lag |
| EP2388285B1 (en) * | 2009-01-16 | 2016-07-06 | Biobase Corporation | Polylactic acid resin composition and additive for polylactic acid resin |
| JP5362400B2 (ja) * | 2009-03-17 | 2013-12-11 | 株式会社クレハ | 低溶融粘度化ポリグリコール酸の製造方法 |
| CN103209704B (zh) | 2010-04-22 | 2017-10-27 | 细胞内治疗公司 | 有机化合物 |
| GB201016433D0 (en) | 2010-09-30 | 2010-11-17 | Q Chip Ltd | Apparatus and method for making solid beads |
| GB201016436D0 (en) | 2010-09-30 | 2010-11-17 | Q Chip Ltd | Method of making solid beads |
| EP2455415A1 (de) * | 2010-11-17 | 2012-05-23 | Evonik Röhm GmbH | Verfahren zur Herstellung von niedermolekularen, resorbierbaren Polyestern, die mit dem Verfahren herstellbaren niedermolekularen resorbierbaren Polyester und deren Verwendung |
| EP2455414A1 (de) * | 2010-11-17 | 2012-05-23 | Evonik Röhm GmbH | Verfahren zur Herstellung von hochmolekularen, resorbierbaren Polyestern, die mit dem Verfahren herstellbaren hochmolekularen resorbierbaren Polyester und deren Verwendung |
| US20120156304A1 (en) * | 2010-12-15 | 2012-06-21 | Thomas Tice | Branched polyol polyesters, blends, and pharmaceutical formulations comprising same |
| CA2870303A1 (en) | 2012-04-14 | 2013-10-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
| JP2014095067A (ja) * | 2012-10-11 | 2014-05-22 | Ricoh Co Ltd | 高分子化合物、包接化合物、シート、および、水分散体 |
| HUE053159T2 (hu) | 2013-03-15 | 2021-06-28 | Intra Cellular Therapies Inc | Szerves vegyületek |
| TW201605488A (zh) * | 2013-10-15 | 2016-02-16 | 大塚製藥股份有限公司 | 用以預防及／或治療多囊腎病之藥物 |
| IL246002B2 (en) | 2013-12-03 | 2024-11-01 | Intra Cellular Therapies Inc | Converted compounds of gamma-carboline fused with heterocycles for use in the treatment of residual symptoms of psychosis and a long-acting injectable preparation containing these compounds in a matrix |
| KR20220054908A (ko) | 2014-04-04 | 2022-05-03 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| JP2017509677A (ja) | 2014-04-04 | 2017-04-06 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 有機化合物 |
| US10179776B2 (en) | 2014-06-09 | 2019-01-15 | Intra-Cellular Therapies, Inc. | Compounds and methods of use to treat schizophrenia |
| JP2016186055A (ja) * | 2015-03-27 | 2016-10-27 | 株式会社クレハ | ポリグリコール酸組成物および一時目止め材 |
| IL318649A (en) | 2016-01-26 | 2025-03-01 | Intra Cellular Therapies Inc | Organic compounds |
| BR112018069594B1 (pt) | 2016-03-25 | 2023-12-05 | Intra-Cellular Therapies, Inc | Compostos orgânicos, composição farmacêutica compreendendo os ditos compostos e uso dos mesmos para o tratamento ou profilaxia de um distúrbio do sistema nervoso central |
| WO2017172795A1 (en) | 2016-03-28 | 2017-10-05 | Intra-Cellular Therapies, Inc. | Novel compositions and methods |
| WO2018071233A1 (en) | 2016-10-12 | 2018-04-19 | Intra-Cellular Therapies, Inc. | Amorphous solid dispersions |
| WO2018126140A1 (en) | 2016-12-29 | 2018-07-05 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EP3562484B1 (en) | 2016-12-29 | 2021-08-25 | Intra-Cellular Therapies, Inc. | Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline derivatives useful in the treatment of cns disorders |
| IL304026B2 (en) | 2017-03-24 | 2024-11-01 | Intra Cellular Therapies Inc | A pharmaceutical preparation containing 1-(4-fluoro-phenyl)-4-((Sa10,Rb6)-3-D2-2,2-methyl-2, 3, a10, 10, 9, b6- hexahydro-H7, H1- Pyrido[3',4',:4,5]pyrrolo[3,2,1-de]quioxalin-8-yl)-butan-1-one and its uses |
| CN111164122B (zh) | 2017-07-07 | 2022-01-04 | 斯蒂潘公司 | 用于聚氨酯应用的低粘度多元醇 |
| MX2020000968A (es) | 2017-07-26 | 2020-09-28 | Intra Cellular Therapies Inc | Compuestos organicos. |
| IL272252B2 (en) | 2017-07-26 | 2024-03-01 | Intra Cellular Therapies Inc | Derivatives of substituted heterocycle fused gamma-carbolines, pharmaceutical compositions comnprising them and their use in treatment |
| US20200281857A1 (en) | 2017-11-22 | 2020-09-10 | Dauntless 1, Inc. | Therapeutic compound formulations |
| US20200353419A1 (en) | 2017-11-22 | 2020-11-12 | Dauntless 1, Inc. | Membrane emulsification device for microsphere creation |
| EP3765021A4 (en) | 2018-03-16 | 2022-03-09 | Intra-Cellular Therapies, Inc. | NOVEL PROCESSES |
| WO2019183341A1 (en) | 2018-03-23 | 2019-09-26 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2019183546A1 (en) | 2018-03-23 | 2019-09-26 | Intra-Cellular Therapies, Inc. | Organic compounds |
| MX2020013335A (es) | 2018-06-08 | 2021-05-27 | Intra Cellular Therapies Inc | Metodos novedosos. |
| WO2020005842A1 (en) | 2018-06-25 | 2020-01-02 | Dauntless 2, Inc. | Membrane emulsification device with impeller for microsphere creation |
| US12144808B2 (en) | 2018-08-29 | 2024-11-19 | Intra-Cellular Therapies, Inc. | Compositions and methods |
| BR112021003838A2 (pt) | 2018-08-31 | 2021-05-18 | Intra-Cellular Therapies, Inc. | métodos novos |
| MX2021002322A (es) | 2018-08-31 | 2021-04-28 | Intra Cellular Therapies Inc | Nuevos metodos. |
| US12195462B2 (en) | 2018-12-17 | 2025-01-14 | Intra-Cellular Therapies, Inc. | Organic compound |
| MX2022000143A (es) | 2019-07-07 | 2022-02-17 | Intra Cellular Therapies Inc | Metodos novedosos. |
| EP4072554A4 (en) | 2019-12-11 | 2023-12-20 | Intra-Cellular Therapies, Inc. | ORGANIC COMPOUND |
| US12414948B2 (en) | 2022-05-18 | 2025-09-16 | Intra-Cellular Therapies, Inc. | Methods |
| JP2026502895A (ja) | 2022-12-30 | 2026-01-27 | イントラ－セルラー・セラピーズ・インコーポレイテッド | セロトニン５－ｈｔ２ａ受容体に作用する複素環縮合ガンマ－カルボリン |
| WO2026011166A1 (en) | 2024-07-03 | 2026-01-08 | Intra-Cellular Therapies, Inc. | Substituted heterocycles for use in the treatment of diseases involving the 5-ht2a receptor |
| WO2026011136A1 (en) | 2024-07-03 | 2026-01-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1020324B (de) * | 1954-12-17 | 1957-12-05 | Boehringer Sohn Ingelheim | Verfahren zur Herstellung von esterartigen Milchsaeurederivaten mit definierter Kettenlaenge und endstaendiger Ester-, Amid- oder Nitrilgruppe |
| FR1584732A (ja) * | 1968-03-13 | 1970-01-02 | ||
| FR1590574A (ja) * | 1968-05-09 | 1970-04-20 | ||
| US3887699A (en) * | 1969-03-24 | 1975-06-03 | Seymour Yolles | Biodegradable polymeric article for dispensing drugs |
| US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IE35855B1 (en) * | 1970-12-18 | 1976-06-09 | Ethicon Inc | Absorbable copolymer suture |
| US3963699A (en) * | 1974-01-10 | 1976-06-15 | The Procter & Gamble Company | Synthesis of higher polyol fatty acid polyesters |
| NO142306C (no) * | 1975-04-18 | 1980-07-30 | Tate & Lyle Ltd | Fremgangsmaate til rensing av et fast stoff i form av et omestringsprodukt frembrakt ved reaksjon mellom sukrose og minst ett fettsyretriglycerid |
| US4328204A (en) * | 1977-03-02 | 1982-05-04 | Ethicon, Inc. | Absorbable polymer-drug compounds and method for making same |
| WO1978000011A1 (fr) * | 1977-06-07 | 1978-12-21 | Garching Instrumente | Forme d'implant medicamenteux et procede de preparation |
| US4130639A (en) * | 1977-09-28 | 1978-12-19 | Ethicon, Inc. | Absorbable pharmaceutical compositions based on isomorphic copolyoxalates |
| US4165432A (en) * | 1977-10-18 | 1979-08-21 | Olin Corporation | Peroxy di-ester polyols |
| DE2824112A1 (de) * | 1978-06-01 | 1979-12-06 | Garching Instrumente | Mikropellets, verfahren zu ihrer herstellung und deren verwendung |
| US4273920A (en) * | 1979-09-12 | 1981-06-16 | Eli Lilly And Company | Polymerization process and product |
| US4334061A (en) * | 1979-10-29 | 1982-06-08 | Ethyl Corporation | Process for recovery of polyol fatty acid polyesters |
| DE3045135A1 (de) * | 1980-11-29 | 1982-06-09 | Sandoz-Patent-GmbH, 7850 Lörrach | Pharmazeutische kompositionen enthaltende bioabbaubare polymere |
| IE52535B1 (en) * | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| ATE37983T1 (de) * | 1982-04-22 | 1988-11-15 | Ici Plc | Mittel mit verzoegerter freigabe. |
| US4452973A (en) * | 1982-11-12 | 1984-06-05 | American Cyanamid Company | Poly(glycolic acid)/poly(oxyethylene) triblock copolymers and method of manufacturing the same |
| FR2537980B1 (fr) * | 1982-12-17 | 1986-12-19 | Sandoz Sa | Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation |
-
1983
- 1983-08-26 CH CH4671/83A patent/CH656884A5/de not_active IP Right Cessation
-
1984
- 1984-08-20 NL NLAANVRAGE8402547,A patent/NL190415C/xx not_active IP Right Cessation
- 1984-08-21 FR FR8413111A patent/FR2551072B1/fr not_active Expired
- 1984-08-21 HU HU843146A patent/HU195426B/hu unknown
- 1984-08-22 DE DE3430852A patent/DE3430852C2/de not_active Expired - Lifetime
- 1984-08-22 GB GB08421273A patent/GB2145422B/en not_active Expired
- 1984-08-22 BE BE1/11073A patent/BE900406A/fr not_active IP Right Cessation
- 1984-08-23 GR GR80184A patent/GR80184B/el unknown
- 1984-08-24 AT AT0271384A patent/AT395584B/de active
- 1984-08-24 PH PH31143A patent/PH23556A/en unknown
- 1984-08-24 IT IT22413/84A patent/IT1176629B/it active Protection Beyond IP Right Term
- 1984-08-24 NZ NZ209335A patent/NZ209335A/xx unknown
- 1984-08-24 SE SE8404225A patent/SE462098B/sv not_active IP Right Cessation
- 1984-08-24 LU LU85514A patent/LU85514A1/fr unknown
- 1984-08-24 ES ES535399A patent/ES8706750A1/es not_active Expired
- 1984-08-24 PT PT79129A patent/PT79129B/pt unknown
- 1984-08-24 JP JP59177375A patent/JPH0819226B2/ja not_active Expired - Lifetime
- 1984-08-24 IE IE217184A patent/IE58818B1/xx not_active IP Right Cessation
- 1984-08-24 ZA ZA846634A patent/ZA846634B/xx unknown
- 1984-08-24 DK DK198404072A patent/DK173556B1/da not_active IP Right Cessation
- 1984-08-24 IL IL72763A patent/IL72763A/xx not_active IP Right Cessation
- 1984-08-24 AU AU32348/84A patent/AU575066B2/en not_active Expired
-
1987
- 1987-09-24 MY MYPI87001920A patent/MY101861A/en unknown
-
1990
- 1990-07-11 SG SG535/90A patent/SG53590G/en unknown
- 1990-08-30 HK HK673/90A patent/HK67390A/xx not_active IP Right Cessation
-
1991
- 1991-03-22 CY CY1556A patent/CY1556A/en unknown
-
1992
- 1992-02-11 US US07/834,018 patent/US5922682A/en not_active Expired - Lifetime
-
1995
- 1995-06-06 US US08/471,304 patent/US5922338A/en not_active Expired - Lifetime
-
1996
- 1996-06-06 NL NL960014C patent/NL960014I1/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5922338A (en) | Polyol esters, their preparation and use in depot forms of pharmacologically active agents | |
| US4882168A (en) | Polyesters containing alkylene oxide blocks as drug delivery systems | |
| US4130639A (en) | Absorbable pharmaceutical compositions based on isomorphic copolyoxalates | |
| EP0058481B1 (en) | Continuous release pharmaceutical compositions | |
| US5849859A (en) | Polyesters | |
| US5366734A (en) | Continuous release pharmaceutical compositions | |
| Kissel et al. | Parenteral depot-systems on the basis of biodegradable polyesters | |
| EP0053580B1 (en) | Pharmaceutical compositions | |
| AU687553B2 (en) | Process for the production of microparticles | |
| AU605172B2 (en) | Polyesters containing alkylene oxide blocks as drug delivery systems | |
| EP0816413B1 (en) | Pharmaceutical composition comprising a purified polylactide and a hydrophilic or lipophilic drug | |
| FR2741628A1 (fr) | Nouveaux hydrogels a base de copolymeres trisequences et leur application notamment a la liberation progressive de principes actifs | |
| GB2165454A (en) | Pharmaceutical depot forms containing bromocriptine | |
| US4186189A (en) | Absorbable pharmaceutical compositions based on poly(alkylene oxalates) | |
| EP0245840B1 (de) | Biologisch abbaubare Polymere für Depotzubereitungen mit kontrollierter Wirkstoffabgabe | |
| Edlund et al. | Novel drug delivery microspheres from poly (1, 5‐dioxepan‐2‐one‐co‐l‐lactide) | |
| KR930002707B1 (ko) | 폴리올 에스테르의 제조방법 | |
| CA1242705A (en) | Esters, their preparation and use | |
| Wada et al. | New biodegradable oligoesters for pharmaceutical application | |
| CY1844A (en) | Sustained release formulations of water soluble peptides | |
| CZ278181B6 (en) | Process of purifying polymers and oligomers of aliphatic hydroxy- acids |